<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="997">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05148169</url>
  </required_header>
  <id_info>
    <org_study_id>201940109</org_study_id>
    <nct_id>NCT05148169</nct_id>
  </id_info>
  <brief_title>A Pilot Study on Effect of add-on Sulforaphane to SSRIs and Application of Niacin Skin Flush Response Test in Major Depressive Disorder</brief_title>
  <official_title>A Pilot Study on Effect of add-on Sulforaphane to SSRIs and Application of Niacin Skin Flush Response Test in Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 12-week, randomized controlled trial (RCT) will be conducted to explore the effect of&#xD;
      add-on sulforaphane (SFN) to selective serotonin reuptake inhibitors (SSRIs) for major&#xD;
      depressive disorder (MDD). This study also aims to explore the value of niacin skin flush&#xD;
      response test in MDD. One hundred adults diagnosed with MDD will be recruited. Then all the&#xD;
      patients will be randomly assigned to SSRI only group and SSRI plus SFN group. Clinical&#xD;
      symptoms and side-effects will be evaluated using the 17-Hamilton Depression Rating Scale&#xD;
      (17-HDRS), the Hamilton Anxiety Scale (HAMA), Treatment Emergent Symptom Scale (TESS), and&#xD;
      Asberg's Rating Scale for Side Effects (SERS) at baseline and weeks 2, 4, 8 and 12 after&#xD;
      treatment. Fifty healthy subjects will be recruited as control group. For all subjects,&#xD;
      testing of niacin skin flush response and serum levels of nuclear factor erythroid-2-related&#xD;
      factor 2(Nrf-2), p-Nrf2, Heme Oxygenase-1 (HO-1), malondialdehyde (MDA) and erythrocyte&#xD;
      glutathion peroxidase (GPX) will be performed at baseline and endpoint. The primary outcome&#xD;
      is the reduction rate in 17-HDRS total score from baseline to the end of the study. The&#xD;
      secondary outcomes include changes in niacin skin flush response test and levels of serum&#xD;
      markers. All the data will be analyzed by SPSS software.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the reduction rate in 17-HDRS total score from baseline to the end of the study</measure>
    <time_frame>at baseline, week 2/4/8/12 after treatment</time_frame>
    <description>Remission is defined as 17-HDRS total score ≤7; Response is defined as ≥50% decrease from 17-HDRS total score at baseline and 17-HDRS total score&gt;7; Nonresponse is defined as having a reduction of&lt;50% on the total score of 17-HDRS comparing with baseline.&#xD;
at baseline, week 2/4/8/12 after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in levels of serum markers from baseline to the end of the study</measure>
    <time_frame>at baseline, week 8-12 after treatment</time_frame>
    <description>changes in levels of serum markers including nuclear factor erythroid-2-related factor 2(Nrf-2), p-Nrf2, Heme Oxygenase-1 (HO-1), malondialdehyde (MDA) and erythrocyte glutathion peroxidase (GPX) from baseline to week 8-12 after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in niacin skin flush response test from baseline to the end of the study</measure>
    <time_frame>at baseline, week 8-12 after treatment</time_frame>
    <description>changes in signals of blood flow (typified by maximum blood flow, MBF) detected by the Doppler Laser Flowmetry during the niacin skin flush response test from baseline to week 8-12 after treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>SSRI group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One SSRI is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SSRI plus Sulforaphane group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One SSRI is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.&#xD;
The oral dose of SFN is based on weight. The usage and dosage are as follows: 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day (containing 411μmol of glucosinolates). Take it once in the morning and evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention is given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSRIs</intervention_name>
    <description>One SSRI(No-specified) is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.</description>
    <arm_group_label>SSRI group</arm_group_label>
    <arm_group_label>SSRI plus Sulforaphane group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>SSRI plus Sulforaphane</intervention_name>
    <description>One SSRI(No-specified) is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.&#xD;
The oral dose of SFN (ZHIYINGUOSU, Shenzhen Fushan Biotech Co. Ltd.) is based on weight. The usage and dosage are as follows: 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day (containing 411μmol of glucosinolates). Take it once in the morning and evening.</description>
    <arm_group_label>SSRI plus Sulforaphane group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. aged 18-60 years;&#xD;
&#xD;
          2. diagnosed with moderate or severe depressive disorder according to the criteria of the&#xD;
             DSM-5;&#xD;
&#xD;
          3. total score of 17-HDRS≥17;&#xD;
&#xD;
          4. never receiving electroconvulsive therapy (ECT)/modified ECT (MECT)/rTMS or other&#xD;
             treatments in the past month;&#xD;
&#xD;
          5. having sufficient audio-visual ability and comprehension;&#xD;
&#xD;
          6. signed informed consent statements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. serious or active somatic illness (abnormal index values were more than twice the&#xD;
             limit of normal);&#xD;
&#xD;
          2. a history of mania/hypomania;&#xD;
&#xD;
          3. current high risk of suicide (score of item 3 of 17-HDRS ≥ 3);&#xD;
&#xD;
          4. pregnant or lactating women, or planning pregnant women;&#xD;
&#xD;
          5. taking immunosuppressants or vitamins recently.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaohua Liu, Dr.</last_name>
    <phone>8613918061085</phone>
    <email>drliuxiaohua@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yifeng Shen, Ph.D</last_name>
      <phone>8621-34773657</phone>
      <email>shenyifeng@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 2, 2021</study_first_submitted>
  <study_first_submitted_qc>December 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>December 6, 2021</last_update_submitted>
  <last_update_submitted_qc>December 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Sulforaphane</keyword>
  <keyword>Niacin skin flush response</keyword>
  <keyword>Marker</keyword>
  <keyword>Add-on</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Flushing</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulforaphane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

